Cancer Immunology and Immunotherapy (Current Topics in Microbiology and Immunology Book 344)

The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These "(Bfirst-in-class" treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy Immune Infiltration In Human Cancer : Prognostic Significance And Disease Control / Wolf H. Fridman ... [et Al.] -- Subversion And Coercion : The Art Of Redirecting Tumor Immune Surveillance / John B. Mumm And Martin Oft -- Stat3 : A Target To Enhance Antitumor Immune Response / Heehyoung Lee ... [et Al.] -- Biology And Clinical Observations Of Regulatory T Cells In Cancer Immunology / Michele W. Teng ... [et Al.] -- Concepts And Ways To Amplify The Antitumor Immune Response / Bent Rubin And Jean Edouard Gairin -- Angiogenesis And The Tumor Vasculature As Antitumor Immune Modulators : The Role Of Vascular Endothelial Growth Factor And Endothelin / Lana E. Kandalaft ... [et Al.] -- Adoptive Cellular Therapy / Stephen A. Grupp And Carl H. June -- Dendritic Cell Subsets As Vectors And Targets For Improved Cancer Therapy / Karolina Palucka ... [et Al.] -- Identification Of Human Idiotype-specific T Cells In Lymphoma And Myeloma / Jinsheng Weng ... [et Al.] -- Modulation Of Ctla-4 And Gitr For Cancer Immunotherapy / Francesca Avogadri ... [et Al.] -- Immunobiology Of Cancer Therapies Targeting Cd137 And B7-h1/pd-1 Cosignal Pathways / Shengdian Wang And Lieping Chen -- Lag-3 In Cancer Immunotherapy / Monica V. Goldberg And Charles G. Drake -- Immunologically Active Biomaterials For Cancer Therapy / Omar A. Ali And David J. Mooney -- Erratum : Identification Of Human Idiotype-specific T Cells In Lymphoma And Myeloma / Jinsheng Weng ... [et Al.]. Glenn Dranoff, Editor. Includes Bibliographical References And Index. Front Matter....Pages i-xiii Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control....Pages 1-24 Subversion and Coercion: The Art of Redirecting Tumor Immune Surveillance....Pages 25-39 STAT3: A Target to Enhance Antitumor Immune Response....Pages 41-59 Biology and Clinical Observations of Regulatory T Cells in Cancer Immunology....Pages 61-95 Concepts and Ways to Amplify the Antitumor Immune Response....Pages 97-128 Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin....Pages 129-148 Adoptive Cellular Therapy....Pages 149-172 Dendritic Cell Subsets as Vectors and Targets for Improved Cancer Therapy....Pages 173-192 Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma....Pages 193-210 Modulation of CTLA-4 and GITR for Cancer Immunotherapy....Pages 211-244 Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways....Pages 245-267 LAG-3 in Cancer Immunotherapy....Pages 269-278 Immunologically Active Biomaterials for Cancer Therapy....Pages 279-297 Erratum to: Identification of Human Idiotype-Specific T Cells in Lymphoma and Myeloma....Pages 299-299 Back Matter....Pages 301-304 Annotation The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment